Scott Swain details the most common roadblocks that pharma companies experience when incorporating real-world data (RWD) in regulatory submissions and looks at how they can be addressed.
Scott Swain, PhD, MPH
Advertisement
Articles by Scott Swain, PhD, MPH
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Eli Lilly to Submit Oral GLP-1 for FDA Priority Review Program: Report
2
GCC Emerges as a New Strategic Anchor for Global Venture Capital
3
Tylenol Maker Sued While Kennedy Says No ‘Sufficient’ Evidence for Autism Link
4
Pharmaceutical Executive Presents: Most Favored Nation Order - How Trump Is Disrupting Pharma
5
